Bile, Microbiome, and Metabolic Health
Bile acids are signaling molecules, not just fat emulsifiers — and the gut microbiome modifies them in ways that affect inflammation, glucose handling, and even brain function. The lever for most healthy adults is the same as everywhere else on this site: a fiber-rich diet, regular exercise and a healthy weight — none of them bile-specific.
For most of the last century, bile acids were treated as little more than biological detergents — soap the liver makes to dissolve dietary fat. That picture is now badly out of date. Every time bile is released, these molecules dock onto specific receptors in the gut, liver, pancreas, fat, and immune tissue, while the gut's own bacteria chemically rewrite them into dozens of variants with different signaling power. The sections below trace how that system works, where it fails in metabolic disease, and — the part that matters most for a healthy person — how little you actually need to do to keep it running well.
The basics
Bile acids are synthesized in the liver from cholesterol, stored in the gallbladder, and released into the small intestine after meals. They emulsify dietary fats, allowing absorption of fats and fat-soluble vitamins. Making bile acids is also the body's main way of getting rid of excess cholesterol.
There are two routes from cholesterol to bile acid. The main one — the classic pathway — is governed by a rate-limiting enzyme, cholesterol 7α-hydroxylase (CYP7A1), and produces the two human primary bile acids, cholic acid and chenodeoxycholic acid; it accounts for the large majority of daily synthesis in healthy adults. A minor alternative pathway contributes the rest and becomes relatively more important in liver disease and in newborns (Strong — established human biochemistry).[1] Much of the fine regulatory detail comes from rodents, whose bile-acid make-up differs from ours (mice produce muricholic acids that humans lack) — a caveat worth keeping in mind for the receptor biology below.
But that's only the beginning. Bile acids also:
- Act as signaling molecules via FXR (farnesoid X receptor) and TGR5 (Takeda G-protein-coupled receptor 5)[2]
- Influence glucose and lipid metabolism through these receptors
- Are extensively modified by the gut microbiome — primary bile acids (made in the liver) become secondary bile acids via bacterial enzymes
- Modulate gut barrier integrity and immune function
How the signaling actually works
Two receptors do most of the metabolic work, and — importantly — they don't always pull in the same direction.
FXR (the farnesoid X receptor) is switched on by bile acids inside cells of the liver, intestine, and elsewhere; chenodeoxycholic acid is its strongest natural trigger. Its headline job is a feedback loop: bile acids returning to the ileum activate FXR there, which releases a hormone called FGF19 (fibroblast growth factor 19; FGF15 in mice) into the portal blood; FGF19 reaches the liver and tells it to stop making more bile acid. This FXR–FGF19 loop is the main brake on bile acid synthesis, and FGF19 also damps down the liver's glucose and fat production (Strong mechanistic evidence, with human relevance supported by FGF19 physiology and drug trials).[3] A familiar dietary quirk runs through this same loop: the oily diterpene cafestol in unfiltered coffee is a potent dietary FXR activator, and by braking the conversion of cholesterol into bile acids it nudges LDL cholesterol upward — one reason paper-filtered coffee is gentler on lipids; see Coffee.
TGR5 (also called GPBAR1) is a surface receptor on gut hormone-releasing cells, brown fat, muscle, and immune cells. When bile acids hit TGR5 on intestinal L-cells, those cells release the gut hormone GLP-1 (glucagon-like peptide-1), improving glucose tolerance. In brown fat and muscle, TGR5 activation ramps up local thyroid-hormone activation and energy expenditure — a thermogenic effect shown mainly in rodents and human cells.[4][5] In people the evidence is thin: in one two-day study, 12 healthy women taking the bile acid chenodeoxycholic acid by mouth had more active brown fat and burned slightly more energy overall, though that bile acid also switches on FXR, so TGR5 is not proven to be the route.[6] Studies of natural bile acid levels are mixed: adults with and without cold-activated brown fat had similar fasting levels of the main bile acids,[7] and in 56 young adults blood bile acids fell by about a quarter over two hours of cold, and only a few minor bile acids, such as glycolithocholic acid, tracked brown fat activity (Strong in rodents and human cells; Weak and unconfirmed as a human effect).[8] There is no approved TGR5 drug, and two problems stand in the way: activating the receptor fills the gallbladder in animals, and the only published human trial of a selective TGR5 agonist — 6 days in 51 adults with type 2 diabetes — gave erratic results, with blood sugar going up at the two lowest doses and not falling at the two highest (Weak — one small, short early-phase trial).[9]
The two receptors work against each other on GLP-1, which is why the simple picture of "more bile acid signaling is better" is misleading. TGR5 raises GLP-1, but intestinal FXR suppresses it (Strong in rodents and human tissue).[10] It is tempting to use this to explain why bile acid sequestrant drugs, which trap bile acids in the gut and so lower FXR signaling there, improve blood sugar. A direct human test points elsewhere: in a small 17-day trial in 15 adults with type 2 diabetes, sevelamer (a phosphate binder that also traps bile acids) lowered fasting and after-meal glucose, yet blocking the GLP-1 receptor did not take the glucose lowering away; only a modest gain in the insulin-producing cells' responsiveness depended on GLP-1. A single dose of colesevelam did not raise GLP-1 either. So GLP-1 looks like a minor part of the story, and the main route is still unknown (Weak-to-moderate — small, short human trials, one using a stand-in drug).[11][12] The practical takeaway: bile acid signaling is a balance of opposing effects, not a single dial to turn up.
The bile-microbiome conversation
The gut microbiome converts primary bile acids into secondary forms that have different biological activity:
| Primary | Secondary | Modification |
|---|---|---|
| Cholic acid | Deoxycholic acid | 7α-dehydroxylation |
| Chenodeoxycholic acid | Lithocholic acid | 7α-dehydroxylation |
Before this conversion can happen, gut bacteria strip off the glycine or taurine that the liver attaches to each bile acid, using enzymes called bile salt hydrolases. Since 2024 that picture has had to be redrawn: the same enzymes also run in reverse, attaching a wide range of amino acids and other small molecules to bile acids to create a third class, the microbially conjugated bile acids, which in human stool reach concentrations as high as the primary and secondary bile acids in the table above (Strong that they exist; what they do for health is not yet known).[13] In cell experiments some of them act on receptors beyond FXR and TGR5 (Weak — cell culture only).[14] The final 7α-dehydroxylation into secondary bile acids is carried out by only a narrow specialist crew: the responsible gene cluster turns up in most people, but in well under 1% of their gut bacteria.[15] The producers grown in the lab so far are a few Clostridium species, but stool gene surveys suggest most carriers belong to a still-uncultured group in the Ruminococcaceae family (Moderate — inferred from gene surveys).[16] Deoxycholic acid is the main product.
Individual bile acids act very differently at the receptors: chenodeoxycholic acid strongly activates FXR, whereas one mouse-specific bile acid (tauro-β-muricholic acid) blocks it. This is how the microbiome sets the tone of host FXR signaling — germ-free mice pile up the antagonist and shut down the FGF15 feedback loop (Strong preclinical, but a key translation caveat: the best-studied antagonist is a rodent bile acid largely absent in humans).[17]
Different microbial species produce different secondary bile acids; microbial composition shapes the bile acid pool, which in turn shapes metabolism.
A healthy microbiome → balanced bile acid signaling → favorable lipid and glucose metabolism.
A dysbiotic microbiome → altered bile acid signaling → contributes to:
- Insulin resistance
- Fatty liver disease (MASLD) progression
- Increased intestinal permeability ("leaky gut")
- Systemic inflammation
- Metabolic syndrome
Why this matters for longevity
Bile-microbiome dysfunction is mechanistically central to:
-
Fatty liver disease — non-alcoholic fatty liver disease, now more often called metabolic dysfunction-associated steatotic liver disease (NAFLD/MASLD), affects roughly a third of adults worldwide (about 38% in the most recent survey years, and rising)[18] and is tightly linked to type 2 diabetes (T2D), cardiovascular disease (CVD), and cirrhosis (Strong for the disease burden; Moderate for the specific bile-signaling contribution, which is mechanistic and observational).
-
Type 2 diabetes — bile acid signaling through FXR and TGR5 modulates GLP-1 secretion and the liver's glucose output (Moderate — consistent mechanism, supported by how bile-targeted drugs move blood sugar, though for sequestrant drugs GLP-1 seems a minor route; see above).
-
Cardiovascular disease — the liver turns cholesterol into bile acids, so bile acid recycling directly affects blood cholesterol. Drugs that trap bile acids in the gut lower LDL cholesterol, and in a large randomized trial in men with high cholesterol one of them, cholestyramine, cut coronary deaths plus nonfatal heart attacks by about 19% (Moderate — one large trial in men, consistent with the wider evidence that lowering LDL prevents heart attacks).[19] Whether bile acid signaling itself affects heart risk is unclear: recent cohort studies disagree, with higher blood levels of some bile acids linked to more heart disease in people newly diagnosed with type 2 diabetes but to fewer cardiovascular deaths in people with existing coronary disease (Weak — observational and inconsistent).[20][21]
-
Cognition / brain health — the gut-brain axis is increasingly implicated in dementia, and bile acids cross the blood–brain barrier and modulate neuroinflammation (Weak-preliminary — largely animal and associational).
-
Colorectal cancer — secondary bile acids, especially deoxycholic acid, are suspected of promoting colorectal cancer, but the human evidence is mixed. A 2025 meta-analysis of small case-control studies found somewhat higher fecal levels of several bile acids, including deoxycholic acid, in people with precancerous colon polyps (adenomas) than in healthy people; in people who already had colorectal cancer, only two primary bile acids (cholic and chenodeoxycholic acid) were clearly higher, and deoxycholic acid was not.[22] Animal work is more direct: in mice, adding the few gut bacteria that turn bile acids into deoxycholic acid increased colon tumours, and a bacterial strain engineered to lack that conversion step caused fewer tumours than its unmodified version (Weak for people — a handful of small observational studies, with reverse causation and confounding possible; the causal evidence comes from animals).[23]
Bariatric surgery: the best human clue
The strongest human hints that bile acids help drive metabolic improvement come from weight-loss surgery. After gastric bypass, fasting bile acids rise, FGF19 rises more after meals, and C4, a blood marker of how fast the liver is making new bile acids, falls — a pattern consistent with more FXR and TGR5 activation.[24] In one bypass cohort, bile acids and FGF19 rose more in people whose diabetes went into remission, and the rise did not track with how much weight they had lost.[25] In a small study where gastric banding (which restricts the stomach without rerouting the gut) and gastric bypass produced the same 20% weight loss, blood bile acids more than doubled after bypass but fell or stayed flat after banding, pointing to an effect of the rerouted anatomy rather than weight loss alone — although in that study the bile acid rise did not predict better insulin release or insulin sensitivity.[26] Newer trial data complicate the story. In a randomized trial comparing two kinds of gastric bypass, each operation shifted bile acids in a different way, yet metabolism improved about equally.[27] And in a randomized trial of gastric bypass versus sleeve gastrectomy in people with type 2 diabetes, blood bile acids rose after both operations in the first year but were back to pre-surgery levels by 5 years, although particular bile acid patterns were still linked to lasting metabolic benefit, which was more durable after bypass.[28] So bile acids look like one contributor among several, not the single driver (Moderate-to-weak — human data, some collected inside randomized surgical trials, but the bile acid findings are small and correlational; causation is not proven).
Bile acids and aging
One secondary bile acid, lithocholic acid, rises in the blood of calorie-restricted mice, and in late 2024 it was reported to reproduce several of restriction's benefits in older mice — better muscle regeneration, grip strength, and insulin sensitivity — by switching on the cellular energy sensor AMPK; it also extended lifespan in worms and flies. The same study tested mouse lifespan too: mice given lithocholic acid from middle age lived about 5–13% longer on median across three groups, but only one of six sex-by-group comparisons, barely, reached statistical significance, so a mammalian lifespan effect is not established (Weak-preliminary — animal work only; no human data).[29] This is a mechanistic lead, not a supplement recommendation. Lithocholic acid is one of the more toxic bile acids: fed to rabbits and monkeys it damages the liver, and although the human liver largely neutralises it by attaching a sulfate group, that is no reason to add more.[30] A standard two-year rodent study found it did not cause cancer on its own,[31] but in rats, bile acids placed in the colon promoted tumours started by another carcinogen, so deliberately taking it is not advisable.[32]
What disrupts the system
Dietary:
- High saturated fat / low fiber Western diet — alters microbiome, raises secondary bile acid load
- Ultra-processed food — linked to fewer barrier-supporting gut bacteria. In mice, common emulsifiers (carboxymethylcellulose, polysorbate 80) thin the gut's protective mucus layer and drive low-grade inflammation; in small, short human trials they shifted gut bacteria and lowered beneficial short-chain fatty acids but did not raise blood markers of gut leakiness or inflammation (Weak — mouse mechanism, early human data).[33][34]
- Excessive alcohol — direct hepatotoxic and microbiome-disrupting
Medical:
- Gallbladder removal (cholecystectomy) — alters bile flow timing; doesn't catastrophically disrupt metabolism but is associated with more fatty liver disease. A meta-analysis pooling seven studies of about 14.6 million people found roughly 50% higher odds of fatty liver disease after gallbladder removal (odds ratio 1.54, 95% CI 1.18–2.01) — a moderate association, but one likely inflated by the shared metabolic risk factors that lead to gallbladder disease in the first place; several of the pooled studies were one-time snapshots that cannot show which came first, and the link faded in the studies with more than 10 years of follow-up (Moderate-to-weak — observational; mouse studies do not consistently reproduce it). That bracketed range is the 95% confidence interval — the span where the true effect most plausibly lies; because it stays above 1.0, the association is unlikely to be pure chance.[35] For colorectal cancer, pooled cohort studies show no clear overall increase after gallbladder removal, though cancer of the right side of the colon may be about 20% more common relative to people who kept their gallbladder (Weak — observational, and the gallstone disease that leads to surgery shares risk factors with colon cancer).[36]
- Antibiotics — some, such as vancomycin, quickly deplete the bacteria that make secondary bile acids.[37] The gut microbiome mostly recovers within about six weeks, though a few species can stay missing for six months or more; whether bile acid levels stay altered that long has not been measured in people (Moderate for the microbiome change; Weak for lasting bile effects).[38]
- Proton-pump inhibitors (PPIs), chronic use — alter gut microbiome composition
Lifestyle:
- Sedentary behavior, obesity, chronic stress
What supports it
Diet:
- Fiber, especially soluble fiber — feeds bile acid-modifying bacteria; binds bile acids and promotes their fecal excretion (driving liver to use cholesterol to make new bile acids — the mechanism behind oat/legume LDL-lowering)
- Polyphenol-rich foods — modulate microbiome
- Fermented foods — yogurt, kefir, sauerkraut, kimchi, miso, tempeh — diversify microbiome
- Mediterranean-pattern eating — multiple components support both bile and microbiome health
- Adequate protein and choline — part of a normal diet: choline goes into phosphatidylcholine, a fat secreted into bile alongside bile acids, and the liver attaches glycine or taurine to bile acids; there is no evidence that eating more of either changes bile acid signaling in adults who already eat enough
Behavioral:
- Time-restricted eating — a regular overnight fast is a reasonable habit, but it has not been shown to change bile acid signaling: when lean adults ate all their food in one evening meal for 11 days, their bile acids and FGF19 did not change (Weak — one small trial).[39]
- Regular physical activity — good for metabolic health in its own right; a single exercise session briefly shifts blood bile acids, but whether regular training changes bile acid signaling in a meaningful way is unknown (Weak).[40]
- Adequate sleep and regular daily rhythms — bile acid production follows a daily clock: in people it peaks during the day (around early afternoon and again in the evening) and falls overnight, the reverse of the rodent pattern (Moderate for the rhythm; no evidence that sleep habits themselves change it).[41]
Pharmacological (in disease):
These are treatments for diagnosed disease, not longevity tools for healthy people. What the trial evidence actually shows:
- Bile acid sequestrants (cholestyramine, colesevelam) — long used to lower LDL cholesterol. The older drug, cholestyramine, has a heart-outcome trial: over about 7 years in 3,806 middle-aged men with high cholesterol, it lowered LDL cholesterol about 13% more than placebo and cut coronary deaths plus nonfatal heart attacks by 19% (7% vs 8.6% of men), with no clear effect on deaths from all causes (Moderate — one large randomized trial, men only, decades old).[42] Colesevelam is also approved as an add-on for type 2 diabetes. Pooled trial data show a meaningful glucose benefit: about a 0.5-percentage-point drop in HbA1c on top of standard diabetes drugs (Strong for the effect size — randomized-trial meta-analysis; colesevelam itself has no heart-outcome trial, and how it lowers glucose is unknown — GLP-1 seems to play only a small part, see above).[43]
- Obeticholic acid — an FXR agonist, and the cautionary tale of this drug class. It won accelerated US approval in 2016 for primary biliary cholangitis, a cholestatic liver disease — a provisional approval granted on condition that a later trial confirm a real benefit. That trial did not: death, liver transplant, or signs of advanced liver disease occurred about equally often on the drug and on placebo (in 28.6% vs 28.9% of patients), although many placebo patients switched to the commercial drug, which blurs the comparison.[44] The EU revoked the approval in 2024 because the benefit was not confirmed.[45] In 2025 the US FDA also found an excess of liver transplants and deaths among trial patients who had started with early-stage disease, and US approval was withdrawn in November 2025.[46] For the inflammatory form of fatty liver disease (steatohepatitis, NASH/MASH) it improved liver scarring in a large phase 3 trial — roughly 23% of patients improved by at least one fibrosis stage versus 12% on placebo — but the US FDA rejected it for that use twice, because the benefit was on a biopsy surrogate rather than hard outcomes and was offset by itching, cholesterol rises, and liver-injury risk (Caution — approval withdrawn in the US and revoked in the EU; never approved for fatty liver disease).[47]
- Newer non-steroidal FXR agonists (cilofexor, tropifexor) — reduced liver fat in phase 2 fatty-liver trials (cilofexor cut liver fat by about 23% at the top dose versus essentially no change on placebo) and caused more itching, but never showed a fibrosis benefit.[48] Both are no longer being developed for fatty liver disease, and the furthest-along FXR drugs left are only in phase 2 (Weak — early trials, no fibrosis or outcome data).[49]
- FGF19 analogs (aldafermin) — engineered to switch on the gut-liver feedback loop directly and cut liver fat; but the larger phase 2b fatty-liver trial missed its main fibrosis target (Weak-preliminary — pivotal endpoint not met; manufacturer-funded).[50]
- Drugs that did win approval for fatty liver disease with scarring do not act on FXR. Resmetirom, a liver-targeted thyroid-hormone mimic, was approved in the US in March 2024 and in the EU in August 2025 for steatohepatitis with moderate-to-advanced scarring (but not cirrhosis). In its main trial, scarring improved by at least one stage in about 24–26% of patients versus 14% on placebo, and LDL cholesterol fell rather than rose.[51] Semaglutide followed in the US in August 2025; see GLP-1 agonists for its trial results.[52] Both were approved early on biopsy improvements, the same kind of evidence obeticholic acid was turned down on; whether they prevent cirrhosis or death is still being tested (Moderate — large manufacturer-funded trials, biopsy endpoints, outcome trials ongoing).
- GLP-1 agonists — established metabolic drugs (semaglutide, tirzepatide) whose gut effects overlap the same GLP-1 pathway bile acids tap through TGR5.
Practical implications
For most healthy adults, you don't need a "bile-targeted" intervention. The standard longevity playbook supports the system:
- Mediterranean / fiber-rich diet with legumes daily, vegetables in volume, whole grains, fish, olive oil, nuts.
- Limit ultra-processed food — linked to a less healthy gut microbiome.
- Regular fasted intervals (12–14 hours overnight at minimum) — reasonable for overall metabolic health, though a specific bile benefit is unproven.
- Move regularly — aerobic exercise modulates microbiome.
- Avoid unnecessary antibiotics and PPIs. Use when medically indicated, not casually.
- Manage weight, especially visceral. Visceral fat drives both insulin resistance and fatty liver disease.
- Limit alcohol — direct hepatic toxicity.
There's no need for "bile salt" or "liver detox" supplements for most adults. The system regulates itself if given:
- A microbiome-friendly diet
- Periodic fasted intervals
- Adequate fiber
- Reasonable body composition
When to investigate further
Consider clinical evaluation if:
- Unexplained elevated liver enzymes (ALT, AST, GGT)
- Fatty liver on imaging (MASLD; often an incidental finding)
- Persistent digestive symptoms (bloating, fat malabsorption)
- Strong family history of liver disease, gallstones, or cholestatic disorders
Useful labs (with your clinician):
- ALT, AST, GGT, alkaline phosphatase
- Lipid panel
- HbA1c or fasting glucose; fasting insulin gives an earlier read on insulin resistance (see midlife labs), though liver guidelines do not require it
- If there are signs of fat malabsorption or a cholestatic disorder: vitamin D and a clotting test (INR), which reflects vitamin K status
- FIB-4 score, a free calculation from age, AST, ALT and platelet count — the recommended first check for liver scarring (fibrosis) in anyone with fatty liver, prediabetes, type 2 diabetes or two or more metabolic risk factors, repeated every 1–2 years. Below 1.3 (below 2.0 over age 65) means low risk; above that, the usual next step is a liver-stiffness scan (transient elastography, such as FibroScan) or the Enhanced Liver Fibrosis (ELF) blood test. The score is less reliable under age 35 (Strong — guideline consensus).[53]
What's overhyped
- "Liver detox" supplements — milk thistle, dandelion root, etc. Limited evidence; no substitute for addressing root causes.
- Coffee enemas, "liver flushes" — no benefit, real risks (rectal trauma, bowel perforation, electrolyte disturbance).
- Specific probiotic products marketed for "gut healing" — most don't have rigorous evidence for general use; targeted strains have specific indications.
Bile and gallstones
Worth a brief note. Risk factors for gallstones (Moderate — consistent but observational epidemiology):
- Female sex, multiple pregnancies, oral contraceptives, hormone replacement therapy (HRT)
- Obesity, metabolic syndrome
- Rapid weight loss (paradoxically)
- Family history
- Specific ethnicities (Native American, certain Hispanic)
Prevention:
- Avoid sustained weight loss faster than about 1.5 kg a week; gallstone risk climbs steeply above that rate (Moderate — pooled older studies).[54]
- Maintain healthy weight gradually
- Keep some fat in the diet while losing weight: in trials of weight-loss diets, versions with more fat led to far fewer gallstones than very-low-fat ones, likely because fat makes the gallbladder empty regularly (Weak — a few small trials, and the result did not hold up in a stricter sequential analysis).[55]
- Coffee consumption (modestly reduces symptomatic gallstone risk in cohorts)
- Adequate fiber and Mediterranean-pattern diet
- If rapid weight loss is planned (bariatric surgery or a very-low-calorie diet), ask your clinician about ursodeoxycholic acid (UDCA), a prescription bile acid. After bariatric surgery, pooled trials found about two-thirds fewer new gallstones, with doses of 500–600 mg a day for 6–12 months effective, though no clear drop in gallbladder removals.[56] Earlier trials in people losing weight by dieting found an even larger effect.[57] But the largest single trial, in 985 people having gastric bypass, found no significant reduction in gallstone symptoms overall; the benefit showed only in those who had no gallstones before surgery (Moderate — consistent pooled trials, but the biggest trial was null overall).[58]
Further reading
- Bile acid–microbiota interactions in cardiometabolic diseases (review). Front Microbiol 2025.[59]
- Regulation of bile acids and their receptor FXR in metabolic diseases. Front Nutr 2024.[60]
- An update on bile acid–regulated signalling in MASLD. Liver Int 2026.[61]
- Gut–brain axis and bile acid signaling. Int J Mol Sci 2025.[62]
- Bi-directional relationship between bile acids and gut microbiota: UDCA, probiotics, dietary interventions in elderly. Int J Mol Sci 2025.[63]
- Gut microbiome–produced bile acid metabolite lengthens the circadian period. PNAS 2026.[64]
- Physiology, Bile Secretion — StatPearls.[65]
- Targeting FXR and FGF19 to treat metabolic diseases — lessons from bariatric surgery. Diabetes 2018.[66]
- Farnesoid X receptor inhibits GLP-1 production by enteroendocrine L cells. Nat Commun 2015.[67]
- Colesevelam for type 2 diabetes mellitus (Cochrane review). Diabet Med 2014.[68]
- Obeticholic acid for NASH — phase 3 REGENERATE interim analysis. Lancet 2019.[69]
- Lithocholic acid phenocopies anti-ageing effects of calorie restriction. Nature 2025.[70]